Strategic Partnership Leverage the recent Versiti partnership to position HematoLogics as a preferred collaboration for hematopathology and flow cytometry services, targeting labs seeking integrated diagnostic workflows and co-developed testing capabilities.

Growth Opportunity With a mid-size revenue base and a specialized niche in residual disease monitoring for leukemia, pursue contracts with larger CROs and diagnostics firms that need expert hematopathology services to expand their offerings.

Technology Enablement Highlight the company’s advanced flow cytometry and cell sorting capabilities as differentiators in competitive bids, and propose joint development of high-sensitivity panels to meet emerging relapse monitoring demands.

Market Fit Target mid-to-large medical labs and diagnostic networks seeking specialized hematopathology and residual disease testing to augment throughput, reduce turnaround times, and improve diagnostic accuracy.

Financial Leverage Position HematoLogics as a cost-effective partner with scalable testing capacity, suitable for long-term service agreements and performance-based pricing tied to improved diagnostic outcomes.